Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.
McHugh D, Eisenberger M, Heath EI, Bruce J, Danila DC, Rathkopf DE, Feldman J, Slovin SF, Anand B, Chu R, Lackey J, Reyno L, Antonarakis ES, Morris MJ. McHugh D, et al. Among authors: eisenberger m. Invest New Drugs. 2019 Oct;37(5):1052-1060. doi: 10.1007/s10637-019-00731-5. Epub 2019 Feb 6. Invest New Drugs. 2019. PMID: 30725389 Free PMC article. Clinical Trial.
Phase II trial of N-methylformamide in advanced renal cancer.
Abrams JS, Tait N, Silva H, Eisenberger M, Van Echo DA, Olver IN, Aisner J. Abrams JS, et al. Among authors: eisenberger m. Am J Clin Oncol. 1989 Feb;12(1):41-2. doi: 10.1097/00000421-198902000-00009. Am J Clin Oncol. 1989. PMID: 2912020
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.
Hudes G, Tagawa ST, Whang YE, Qi M, Qin X, Puchalski TA, Reddy M, Cornfeld M, Eisenberger M. Hudes G, et al. Among authors: eisenberger m. Invest New Drugs. 2013 Jun;31(3):669-76. doi: 10.1007/s10637-012-9857-z. Epub 2012 Jul 25. Invest New Drugs. 2013. PMID: 22828917 Clinical Trial.
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.
Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin SF, DeLaCruz A, Lee Y, Webb IJ, Scher HI. Galsky MD, et al. Among authors: eisenberger m. J Clin Oncol. 2008 May 1;26(13):2147-54. doi: 10.1200/JCO.2007.15.0532. Epub 2008 Mar 24. J Clin Oncol. 2008. PMID: 18362364 Clinical Trial.
351 results